Clinical Trial

MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary objective of this trial is to evaluate the effect of oral ECC4703 on body weight reduction and in a sub-study on liver fat content as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 20.
Protocol Amendment History 3 changes
critical Trial status changed: Not Yet Recruiting → Active, Not Recruiting 2026-06-26
notable Primary completion moved earlier: 2026-11-20 -> 2026-10-15 2026-06-26
minor Completion moved earlier: 2026-11-20 -> 2026-10-15 2026-06-26
Trial Details
NCT Number NCT07505303
Lead Sponsor Eccogene
Conditions Adult Obesity, Weight Management
Enrollment 151 participants
Start Date 2026-03-23
Primary Completion 2026-10-15 (estimated)
Study Completion 2026-10-15 (estimated)
Updated on ClinicalTrials.gov 2026-06-25